Key Publications

Granger A, Abdullah I, Huebner F, Stout A, Wang T, Huebner T, Epstein JA, Gruber PJ. Histone deacetylase inhibition reduces myocardial ischemia-reperfusion injury in mice. FASEB J. 2008 Oct;22(10):3549–3560.

Kloner RA. Current State of Clinical Translation of Cardioprotective Agents or Acute Myocardial Infarction. Circ Res. 2013;113:451-463.

Xie M, Kong Y, Tan W, May H, Battiprolu PK, Pedrozo Z, et al. Histone Deacetylase Inhibition Blunts Ischemia/Reperfusion Injury by Inducing Cardiomyocyte Autophagy. Circulation. 2014 Mar 11;129(10):1139–1151.

Relevant Publications

Atar D et al. Effect of intravenous TRO40303 as an adjunct to primary percutaneous coronary intervention for acute ST-elevation myocardial infarction: MITOCARE study results. Eur Heart J. first published online September 1, 2014.

Cai YY, Yap CW, Wang Z, Ho PC, Chan SY, Ng KY, Ge ZG. Solubilization of vorinostat by cyclodextrins. J. of Clinical Pharmacy and Therapeutics. 2009;34:1-6.

Chakrabarti AK, et al. Rationale and design of the EMBRACE STEMI Study: A phase 2a, randomized, double-blind, placebo-controlled trial to evaluate the safety, tolerability and efficacy of intravenous Bendavia on reperfusion injury in patients treated with standard therapy including primary percutaneous coronary intervention and stenting for ST-segment elevation myocardial infarction. Am Heart J. 2013;165:509-514.

Faraco G, Pancani T, Formentini L, Mascagni P, Fossati G, Leoni F, et al. Pharmacological Inhibition of Histone Deacetylases by Suberoylanilide Hydroxamic Acid Specifically Alters Gene Expression and Reduces Ischemic Injury in the Mouse Brain. Mol Pharmacol. 2006 Dec 1;70(6):1876–1884.

Formisano L, Noh KM, Miyawaki T, Mashiko T, Bennett MV, Zukin RS. Ischemic insults promote epigenetic reprogramming of μ opioid receptor expression in hippocampal neurons. Proc. Natl. Acad. Sci. U. S. A. 2007;104:4170–4175.

Go AS et al. Heart Disease and Stroke Statistics−−2014 Update: A Report From the American Heart Association. Circulation. 2014; 129:e28-e292.

Hausenloy DJ, Bøtker HE, Condorelli G, Ferdinandy P, Garcia-Dorado D, Heusch G, et al. Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. Cardiovasc Res. 2013 Apr 1;98(1):7–27.

Kelly WK, Richon VM, O’Connor O, Curley T, MacGregor-Curtelli B, Tong W, et al. Phase I clinical trial of histone deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer Res. 2003 Sep 1;(9):3578–88.

Kelly WK, O’Connor O, Krug LM, Chiao JH, Heaney M, et al. Phase I Study of an Oral Histone Deacetylase Inhibitor, Suberoylanilide Hydroxamic Acid, in Patients With Advanced Cancer. J Clin Oncol. 2005;23:3923-3931.

Piot C et al. Effect of Cyclosporine on Reperfusion Injury in Acute Myocardial Infarction. N Engl J Med. 2008;359:473-81.

O’Gara PT et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;61:e78–140.

Simmons D. Epigenetic influence and disease. Nature Education. 2008; 1(1):6.

Yellon DM, Hausenloy DJ. Myocardial Reperfusion Injury. N Engl J Med. 357:1121-1135, 2007.